



NodThera to present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Boston, MA, February 23, 2026 – NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address cardiometabolic and neuroinflammatory diseases driven by the NLRP3/IL-6/IL-1 inflammation pathway, today announced that Geoff McDonough, M.D., Chief Executive Officer of NodThera, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held February 25-26, 2026, in a virtual format.

Details of the presentation are as follows:

Oppenheimer 36th Annual Healthcare Life Sciences Conference

Date: Thursday, February 26, 2026

Time: 11:20 AM ET

Presenter: Geoff McDonough, M.D.

Location: virtual

About NLRP3

NLRP3 is an upstream activator of proinflammatory cytokines, including IL-6, IL-18 and IL-1 β . Chronic activation of NLRP3 drives pathologic inflammation in cardiometabolic, neurological and other diseases. NLRP3 inhibition with targeted oral therapies reduces systemic inflammation to a similar degree as biologics and does not cause immunosuppression.

About NodThera

NodThera is the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address unmet needs in cardiometabolic and neuroinflammatory diseases driven by the NLRP3/IL-6/IL-1 inflammation pathway.

NodThera is backed by top-tier investors including Blue Owl Capital, Novo Holdings, F-Prime Capital, 5AM Ventures, Sofinnova Partners, Epidarex Capital, and Sanofi Ventures.

NodThera is headquartered in Boston, Massachusetts, with an R&D base in the UK.

Learn more at www.nodthera.com or follow the Company on [LinkedIn](#).

Investors and Media

Argot Partners

nodthera@argotpartners.com